IIT Hyderabad and Deakin University deepen partnership with launch of Advanced Manufacturing Research Innovation and Training (AMRIT)
HYDERABAD, India , May 1, 2025 /PRNewswire/ — In a significant move to strengthen India's manufacturing capabilities, the Indian Institute of Technology Hyderabad (IITH) and Deakin University , Australia , launched the Advanced Manufacturing Research Innovation and Training (AMRIT), a strategic bilateral initiative aimed at advancing next-generation manufacturing technologies, innovation, and workforce development.
AMRIT builds on more than five years of collaboration between IITH and Deakin University , testifying far-reaching future impact possible through strategic institutional partnerships. This new venture is all set to drive research excellence in areas such as additive manufacturing, smart materials, lightweight composites, automation, and Industry 4.0 technologies. It also aims to catalyse the transformation of India's manufacturing sector by bridging academic research with industry needs.
'AMRIT represents a forward-looking step in collaborative innovation, designed to equip India's manufacturing sector with the tools, talent, and technology to lead globally. It is an extension of a longstanding multidimensional partnership with Deakin University , and I expect great outcomes through it,' said Professor B.S. Murty , Director, IIT Hyderabad.
At the heart of the initiative is a focus on capacity building. AMRIT will offer training, certification, and mobility programs to equip professionals and students with the skills required in a rapidly evolving industrial landscape. It will serve as a launchpad for collaborative PhD programs, joint master's programs, and supervision, along with a strong focus on entrepreneurship through startup incubation.
Seed funding of AUD 150,000 from Deakin University and a matching contribution from IIT Hyderabad of AUD 75,000 will support the initial three-year phase, covering research mobility, joint academic programs, workshops, and operational activities. Both institutions also aim to seek further bilateral support from Indian and Australian government funding bodies, including SPARC and AISRF, as well as partnerships with industry and R&D organisations.
'We look forward to deepening our partnership with IIT Hyderabad through AMRIT. It is an inspiring model of how international collaboration can empower research, innovation, and talent development to advance mutually beneficial outcomes,' said Professor Iain Martin , Vice Chancellor, Deakin University .
Expected to generate high-impact research outcomes, foster innovation ecosystems, and produce a future-ready workforce, AMRIT is positioned to contribute directly to India's ambitions of becoming a global hub for advanced manufacturing.
' Deakin has had a deep and enduring commitment to India for nearly three decades. AMRIT is the next big step in our journey aimed at creating a holistic platform for research, innovation, and skill-building that will shape the future of manufacturing. It reflects our vision to co-create solutions with India that have global relevance and impact,' said Ravneet Pawha , Vice President (Global Engagement) and CEO ( South Asia ), Deakin University .
Over the past five years, IIT Hyderabad and Deakin University have nurtured a robust and evolving partnership rooted in academic and research collaboration. The two institutions have worked closely through a Joint Doctoral Program (30 students of IITH are pursuing JDP with Deakin ), faculty and student exchanges, and joint research initiatives, particularly in the areas of advanced manufacturing and materials. The launch of AMRIT marks the next big step in this journey, elevating their shared vision to create global impact through innovation, skilling, and knowledge exchange.
To find out more about the Deakin University and IIT Hyderabad partnership, please visit Deakin South Asia Partnerships.
About Deakin University :
Established in 1974, Deakin University successfully combines excellence in teaching, research and effective partnerships with industry and government to deliver high-quality courses and undertake research that makes a difference to the domestic and international communities it serves.
Deakin's South Asia operations commenced in 1994 at New Delhi, India , making it one of the first overseas education provider to set operations in this region. Here, Deakin engages with the government, industry, and academia to share its vibrant culture of education and research.
To find out more please visit https://www.deakin.edu.au/
About IIT Hyderabad:
IITH, established in 2008, has reached a respectable position in academics, research, technology development and Startups in the short span of 16 years. In the recent Indian National Ranking (NIRF-2024), IITH is ranked 3rd in Innovation and 8th among Engineering institutes in India . IITH has been striving for excellence in academics, research, technology development and the startup ecosystem with a motto of 'Inventing & Innovating in Technology for Humanity (IITH)'.
With 325+ full-time faculty and 5,300+ students (PG+PhD students accounting for about 60%), IITH has a strong research focus with ~4500 projects worth of Rs. 1400+ Cr of R&D funding (Rs. 335+ Cr in 2024-25), 11,500+ publications, 2,15,000+ citations, 500+ Patents (210 patents in 2024 and a commitment to 'Patent a Day: Mission 365' for 2025 to earn 365 patents by the end of 2025), and about 260+ Startups (that have generated 1100+ jobs with a revenue of Rs. 1500+ Cr). The attached documents will give you a brief about IITH.
Photo: https://mma.prnewswire.com/media/2677814/DEAKIN_IITH_AMRIT.jpg
View original content to download multimedia:https://www.prnewswire.com/in/news-releases/iit-hyderabad-and-deakin-university-deepen-partnership-with-launch-of-advanced-manufacturing-research-innovation-and-training-amrit-302443810.html
Disclaimer: The above press release comes to you under an arrangement with PR Newswire. Business Upturn takes no editorial responsibility for the same.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Mesoblast (ASX:MSB) Gains 15% In One Week With US FDA Orphan-Drug Approval
Mesoblast experienced a 15% increase in its share price over the past week, largely driven by a significant orphan-drug approval by the U.S. FDA for Ryoncil. This approval, granting seven years of exclusivity for a vital treatment, likely bolstered investor confidence given the strengthened competitive positioning of Mesoblast. While broader market trends saw the S&P 500 and Nasdaq reach new highs amid positive investor sentiment on U.S.-China trade discussions, Mesoblast's specific gains were more tied to its unique developments, as they provided a substantial boost, counterbalancing broader market movements. You should learn about the 1 warning sign we've spotted with Mesoblast. Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. Over the past three years, Mesoblast's total shareholder return, including share price changes and dividends, reached 181.00%. Despite recent gains driven by the U.S. FDA's orphan-drug approval for Ryoncil, the company's one-year performance outpaced the broader Australian Biotechs industry, which returned 12.3% less in the same timeframe. This highlights significant investor confidence and a positive reception to recent strategic advancements. While Mesoblast's share price has experienced impressive growth, it still trades at approximately 88% below consensus analyst price targets. The approval of Ryoncil positions the company competitively, potentially boosting future revenue, as evidenced by the expanded insurance coverage to 104 million U.S. lives. However, Mesoblast remains unprofitable, with A$47.93 million in net losses reported in its recent earnings. Analysts forecast substantial revenue growth at 56.7% annually, but profit forecasts show continued challenges for the next three years. The stock's recent appreciation reflects increased optimism, although the gap between the current share price and targeted fair value suggests room for further market adjustments. Our comprehensive valuation report raises the possibility that Mesoblast is priced lower than what may be justified by its financials. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:MSB. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
19 minutes ago
- Business Upturn
Nomura upbeat on Dr. Reddy's long-term prospects; maintains ‘Buy' call with Rs 1,575 target
By Markets Desk Published on June 12, 2025, 07:38 IST Nomura has maintained its Buy rating on Dr. Reddy's Laboratories, setting a target price of ₹1,575, following the company's strategic roadmap shared during a recent management interaction. The company laid out four key levers to sustain growth and profitability beyond the gRevlimid opportunity, including: Sustained growth in the base business, Significant upside potential from semaglutide, the blockbuster diabetes and weight-loss drug, Capacity to undertake selective acquisitions in the $2–2.5 billion range, and A strong focus on cost rationalisation, with plans to reduce operating expenses by 500 basis points — from 37% to 32% of sales — thereby maintaining EBITDA margins around 25%. Dr. Reddy's, a major Indian pharmaceutical company with a strong global presence, has expanded its footprint across generics, biosimilars, and active pharmaceutical ingredients (APIs). It has also been building its presence in high-value markets like the US, Europe, and emerging markets through a mix of organic growth and strategic deals. Nomura believes the combination of margin optimisation, pipeline monetisation (including complex generics like semaglutide), and balance sheet flexibility places the company in a strong position for long-term value creation. Disclaimer: The views and target prices mentioned are as stated by Nomura and do not represent the opinions or recommendations of this publication. Investors are advised to consult their financial advisors before making any investment decisions. Markets Desk at
Business Upturn
19 minutes ago
- Business Upturn
Jefferies bullish on real estate pre-sales; sees rate cuts boosting mid-income housing
By Markets Desk Published on June 12, 2025, 07:49 IST Jefferies has turned increasingly constructive on the Indian real estate sector, expecting pre-sales growth for listed developers to rise over 20% in FY26, up from 15% in FY25. The brokerage cited strong project launch activity in Q1FY26, which lends credibility to developer guidance, contrasting the patchy execution seen last year. It further noted that the recent rate cuts by the RBI are a relief for the mid-income and affordable housing segments, improving affordability and mortgage flow. Despite the sharp rally in property stocks over the past year, Jefferies pointed out that most names continue to trade in line with their 5-year NAV premiums, leaving room for re-rating if visible sales growth persists. Top picks include DLF, Godrej Properties (GPL), and Lodha (Macrotech Developers). Disclaimer: The views and target prices mentioned are as stated by Jefferies and do not represent the opinions or recommendations of this publication. Investors are advised to consult their financial advisors before making any investment decisions. Markets Desk at
